Bill > HR0100

This resolution urges the U.S. Congress to consider passing legislation proposed by the Nu Paradigm Foundation to promote equitable access to medication through more representative clinical drug trials. The proposed legislation would require drug trial sponsors to submit a diversity plan as part of their Investigational New Drug (IND) application, ensuring that clinical trial participants reflect the demographics of the intended patient population, including considerations of age, gender, race, ethnicity, socioeconomic status, and health conditions. The U.S. Food and Drug Administration (FDA) would be responsible for reviewing these diversity plans, potentially withholding drug approval if adequate demographic representation is not demonstrated, and publishing aggregate data on trial participant demographics. Additionally, the U.S. Department of Health and Human Services would establish a task force to oversee the implementation of the legislation, provide guidance to sponsors, and evaluate strategies for enhancing demographic representation in clinical trials. The proposed legislation would take effect 180 days after enactment, with the ultimate goal of ensuring that medication development and testing are more inclusive and representative of diverse populations.

https://www.ilga.gov/legislation/BillStatus.asp?DocNum=100&GAID=18&DocTypeID=HR&SessionID=114&GA=104